Medigene extends cancer immunotherapy alliance with bluebird bio
Category: #health  By Saipriya Iyer  Date: 2018-05-16
  • share
  • Twitter
  • Facebook
  • LinkedIn

Medigene extends cancer immunotherapy alliance with bluebird bio

Medigene AG, a Germany-based biotech firm, and bluebird bio Inc., have reportedly decided to extend their collaboration over cancer immunotherapy. The strategic move may plausibly be aimed at producing a revenue of over USD 509 million for Medigene.

Reportedly, both the firms have decided to increase the number of target antigens/major histocompatibility complex restriction combinations from four to six for the discovery of particular TCR lead candidates. Sources also claimed that the partnership is targeted toward the development of two more TCR-T cancer treatments.

Celgene Corporation, a U.S. based biotech firm, has agreed to shell out a one-time installment of USD 8 million to Medigene. It has been speculated that Celgene will pay nearly up to USD 250 million in terms of milestone payments for two novel TCR ventures. As per reliable sources, Celgene Corp. is also expected to pay double-digit tiered royalties on the net sales of these successful TCR programs.

If reports are to be relied on, the deal between Medigen & bluebird bio Inc., which was estimated at over USD 1 billion in 2016, will help in the integration of Medigen’s TCR isolation & characterization platform with bluebird bio’s manufacturing, lentiviral vector, synthetic biology, and gene-editing proficiencies. Experts familiar with the matter have claimed that TCR tool developed by Medigene AG has been designed to alter T-cells of the cancer patient with tumor-specific TCRs, thereby generating cells that would be able to aptly identify and destroy cancer tumor cells.

As per the terms & conditions stated in the agreement, bluebird bio has taken the responsibility for preclinical as well as clinical growth & commercialization of TCR-T candidates. In return, the company is likely to acquire a license for the specific TCRs patents. Some of the key officials of Medigene have stated that EBITDA guidance, revenue, and R&D funding will remain unaltered though the agreement is extended.



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Foodics enters Egypt market by setting an on-ground presence in Cairo
Foodics enters Egypt market by setting an on-ground presence in Cairo
By Saipriya Iyer

Saudi Arabia-based restaurant management platform Foodics, has announced that it has entered the Egyptian market by creating an on-the-ground presence in Cairo.  The expansion comes after the company raised USD 4 ...

Food Emulsifiers Market to Witness an Appreciable Growth By 2026
Food Emulsifiers Market to Witness an Appreciable Growth By 2026
By Saipriya Iyer

This advanced report on the Food Emulsifiers Market includes of an in-depth overview of this business sphere. Alongside, details of the present market size and status have been given. The report aims to provide substantial updates on the market, p...

Bharat Biotech reveals positive data from animal trial of Covaxin
Bharat Biotech reveals positive data from animal trial of Covaxin
By Saipriya Iyer

Bharat Biotech, an Indian biotechnology company, has reportedly revealed positive results from the animal trial of Covaxin, India’s COVID-19 vaccine candidate.

In the animal t...